Navigation Links
Rigel to Host Conference Call on February 3, 2009
Date:2/2/2009

SOUTH SAN FRANCISCO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company will host a conference call with simultaneous webcast on Tuesday, February 3, 2009 at 8:30 am EST (5:30 am PST). Members of Rigel's senior management team will provide an update on the Company's business plans and programs.

Conference Call and Webcast Information

To access the live call, please dial 800-299-7098 (domestic) or 617-801-9715 (international) 10 minutes prior to the start time and use the passcode 29850656. A replay of the call will be available, in podcast format, at approximately 9:30 a.m. EST on February 3, 2009 until February 10, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 98995701. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, throm
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
8. Rigel Announces First Quarter 2008 Financial Results
9. Rigel to Present at Collins Stewart Growth Conference
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Rigel to Webcast Investor Update on October 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... genetic blood test that allows a much closer match between ... result than the existing tests. The current tests look for ... ,A spokeswoman for the National Blood Service, which is ... for those needing regular transfusions. It is hoped the test ...
... the direct, linear relationship between the sequence of a ... colinearity of DNA and protein sequences is thought to ... However, a paper published today in Science by a ... Institute for Cancer Research (LICR) and the Seattle-based Fred ...
... lot of skincare products, said that its new hand gel ... in 30 seconds.// ,Dermasalve Sciences added that it ... Virology research company for the hand gel, which was jointly ... also said that the tests confirmed that it had a ...
... are at a higher risk of developing HIV/AIDS, Sudanese Minister ... warned. Khartoum Monitor// reports that Magaya issued the warning at ... ,Magaya said that the influx of refugees from other countries ... challenge is how to reduce the danger in south Sudan. ...
... convicted last month of illegal abortions, said she will not ... South Wales (NSW) Medical// Tribunal. ,Suman Sood, 56, ... Sydney Morning Herald newspaper. ,"I have decided ... the medical tribunal proceedings. ,"I have accepted ...
... are exposed to certain harmful chemicals before they are even ... need for pregnant women to be careful about their diet.// ... the University of Granada, Spain, tested blood samples taken from ... different types of pesticide, reported the online edition of Daily ...
Other Medicine News:Health News:Novel genetic blood test 2Health News:Protein Splicing Upsets the DNA Colinearity Paradigm 2Health News:Babies in Womb Exposed to Harmful Chemicals 2
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... 17 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... International Conference on Antiviral Research (ICAR) in Montreal,Quebec, ... of the hepatitis C virus (HCV) NS5b polymerase., ... ANA598 that,support the potential for beneficial combination of ...
... 17 An optimized PARI eFlow,platform nebulizer will ... clinical trial that has begun enrolling patients. ALN-RSV01 ... for respiratory syncytial virus,(RSV) infection, the leading cause ... infection in immune-compromised adults. RSV currently does,not have ...
Other Medicine Technology:Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 2Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 3PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 2
... When Welch Allyn designed the ... in 1915, they began a tradition ... eye care professionals worldwide. In keeping ... introduces the prestigious 3.5v Coaxial-plus Ophthalmoscope. ...
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... ALE-3600 and ALE-3600PC Patternless ... fit lenses to frames, ... the convenience of complete ... edgers are particularly suited ...
... the features of the FR-20 Frame Reader with ... no longer need to connect the frame reader ... capable of receiving data via a cable from ... to streamline your edging operations. It stores the ...
Medicine Products: